Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 169

Sort by

Sort Order Select

Journal Articles

Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients

Michikata Hayashida, Aya Nishida, Mika Kuno, Otoya Watanabe, Daisuke Kaji, Yuki Taya, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, Suguru Oka, Kazushige Sakaguchi, Shinji Urakami, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 2162.

https://doi.org/10.1182/blood-2024-199936

Published: 2024

Journal Articles

Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation

Shunsuke Nishino, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Kazuya Ishiwata, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2024-205008

Published: 2024

Journal Articles

Kinetics of Recipients with Thrombocytopenia and Its Impact on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study

Blood (2024) 144 (Supplement 1): 2121.

https://doi.org/10.1182/blood-2024-201927

Published: 2024

Journal Articles

Retrospective Analysis of Single-Unit Umbilical Cord Blood Transplantation in Elderly Patients (Aged 65 Years and Older) with Predominantly High-Risk Myeloid Malignancies: A Single-Institution Study

Yuki Taya, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 7437.

https://doi.org/10.1182/blood-2024-208778

Published: 2024

Journal Articles

Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

Blood (2024) 144 (Supplement 1): 384.

https://doi.org/10.1182/blood-2024-203344

Published: 2024

Journal Articles

What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes

Jotaro Yamamoto, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Kazuya Ishiwata, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 3485.

https://doi.org/10.1182/blood-2024-201930

Published: 2024

Journal Articles

Frequent Loss of HLA-B*40:02 from Leukocytes in Male Patients with Hepatitis-Associated Aplastic Anemia

Blood (2024) 144 (Supplement 1): 1311.

https://doi.org/10.1182/blood-2024-197892

Published: 2024

Journal Articles

Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL

Ryo Koizumi, Shinsuke Takagi, Aya Nishida, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Kazuya Ishiwata, Hisashi Yamamoto, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2024-203327

Published: 2024

Journal Articles

Transformative Outcomes with Short-Term Blinatumomab and Cord Blood Transplantation in Relapsed/Refractory B-Cell ALL

Aya Nishida, Mika Kuno, Otoya Watanabe, Daisuke Kaji, Yuki Taya, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 7304.

https://doi.org/10.1182/blood-2024-198310

Published: 2024

Journal Articles

Prognostic Impact of Graft-Versus-Host Disease on Allogeneic Transplantation for CMML Focusing on Conditioning Intensity

Hidehiro Itonaga, Yasushi Miyazaki, Machiko Fujioka, Shuhei Kurosawa, Yasunobu Nagata, Yutaka Shimazu, Tomoaki Ueda, Naoyuki Uchida, Noriko Doki, Tetsuya Nishida, Ken-ichi Matsuoka, Masatsugu Tanaka, Makoto Yoshimitsu, Yoshinobu Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Takayoshi Tachibana

Blood (2024) 144 (Supplement 1): 6755.

https://doi.org/10.1182/blood-2024-193699

Published: 2024

Journal Articles

Combined Targeting Patient-Specific Anti-Apoptotic Molecules and CXCR4-Expressing CAR-T Cells Eliminated High-Inflammation State Leukemia with Poor-Prognostic Mutations

Blood (2024) 144 (Supplement 1): 1453.

https://doi.org/10.1182/blood-2024-204989

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma with Stable or Progressive Disease

Kimimori Kamijo, Yoshimitsu Shimomura, Naoyuki Uchida, Satoshi Yoshihara, Takahiro Fukuda, Yasufumi Uehara, Yasuo Mori, Tetsuya Eto, Hikaru Kobayashi, Kentaro Serizawa, Tatsuo Ichinohe, Makoto Yoshimitsu, Junya Kanda, Yoshiko Atsuta, Shinichi Kako

Blood (2024) 144 (Supplement 1): 2166.

https://doi.org/10.1182/blood-2024-206578

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia with t(16;21)(p11;q22)

Satoshi Mitsuyuki, Yoshimitsu Shimomura, Hiroki Mizumaki, Masamitsu Yanada, Shohei Mizuno, Naoyuki Uchida, Noriko Doki, Ayumu Ito, Masatsugu Tanaka, Tetsuya Nishida, Yuta Katayama, Satoshi Yoshihara, Tetsuya Eto, Koji Kawamura, Makoto Onizuka, Takahiro Fukuda, Marie Ohbiki, Yoshiko Atsuta, Takaaki Konuma

Blood (2024) 144 (Supplement 1): 1469.

https://doi.org/10.1182/blood-2024-198750

Published: 2024

Journal Articles

Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms

Otoya Watanabe, Hisashi Yamamoto, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 4933.

https://doi.org/10.1182/blood-2024-210383

Published: 2024

Journal Articles

Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis

Shotaro Shimada, Naoyuki Uchida, Hisashi Yamamoto, Otoya Watanabe, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Yuki Asano-Mori, Go Yamamoto

Blood (2024) 144 (Supplement 1): 4926.

https://doi.org/10.1182/blood-2024-207383

Published: 2024

Journal Articles

Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status

Tatsuro Hirao, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 4920.

https://doi.org/10.1182/blood-2024-198879

Published: 2024

Journal Articles

Optimal Procedures of Allogeneic Transplantation for BCR::ABL1 -Negative Atypical Chronic Myeloid Leukemia

Hidehiro Itonaga, Yasushi Miyazaki, Takeshi Kondo, Yutaka Shimazu, Jun Aoki, Shuhei Kurosawa, Takashi Ikeda, Tetsuya Eto, Naoyuki Uchida, Hideyuki Nakazawa, Koji Kawamura, Junya Kanda, Yoshiko Atsuta, Takayoshi Tachibana

Blood (2024) 144 (Supplement 1): 4548.

https://doi.org/10.1182/blood-2024-193697

Published: 2024

Journal Articles

The HLA-B Leader MM Genotype Has a Negative Impact on Outcomes in HLA-B One Antigen Mismatched and HLA-B Matched Cord Blood Transplantation without Anti-Thymocyte Globulin: Analysis of the Japanese Society for Transplantation and Cellular Therapy

Blood (2023) 142 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2023-178905

Published: 2023

Journal Articles

Impact of Letermovir Prophylaxis for Cytomegalovirus Reactivation on Post-Transplant Outcomes 100 Days before and after Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4898.

https://doi.org/10.1182/blood-2023-180906

Published: 2023

Journal Articles

Cytomegalovirus-Seronegative Plus Leukoreduced Blood Products Are Still Superior to Only Leukoreduced Products in Preventing Transfusion-Transmitted Cytomegalovirus Infection

Kimikazu Yakushijin, Ryu Yanagisawa, Sachiko Seo, Masao Ogata, Michiko Kajiwara, Naoyuki Uchida, Youko Suehiro, Noriko Doki, Daiichiro Hasegawa, Satoshi Yoshihara, Kensuke Usuki, Katsuyoshi Koh, Yoshinobu Kanda, Mineo Kurokawa, Makoto Onizuka, Fumihiko Ishimaru, Yoshiko Atsuta, Takahiro Fukuda, Hideki Nakasone

Blood (2023) 142 (Supplement 1): 2666.

https://doi.org/10.1182/blood-2023-178182

Published: 2023

NARROW

Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients

Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation

Kinetics of Recipients with Thrombocytopenia and Its Impact on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study

Retrospective Analysis of Single-Unit Umbilical Cord Blood Transplantation in Elderly Patients (Aged 65 Years and Older) with Predominantly High-Risk Myeloid Malignancies: A Single-Institution Study

Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes

Frequent Loss of HLA-B*40:02 from Leukocytes in Male Patients with Hepatitis-Associated Aplastic Anemia

Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL

Transformative Outcomes with Short-Term Blinatumomab and Cord Blood Transplantation in Relapsed/Refractory B-Cell ALL

Prognostic Impact of Graft-Versus-Host Disease on Allogeneic Transplantation for CMML Focusing on Conditioning Intensity

Combined Targeting Patient-Specific Anti-Apoptotic Molecules and CXCR4-Expressing CAR-T Cells Eliminated High-Inflammation State Leukemia with Poor-Prognostic Mutations

Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma with Stable or Progressive Disease

Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia with t(16;21)(p11;q22)

Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms

Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis

Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status

Optimal Procedures of Allogeneic Transplantation for BCR::ABL1 -Negative Atypical Chronic Myeloid Leukemia

The HLA-B Leader MM Genotype Has a Negative Impact on Outcomes in HLA-B One Antigen Mismatched and HLA-B Matched Cord Blood Transplantation without Anti-Thymocyte Globulin: Analysis of the Japanese Society for Transplantation and Cellular Therapy

Impact of Letermovir Prophylaxis for Cytomegalovirus Reactivation on Post-Transplant Outcomes 100 Days before and after Allogeneic Hematopoietic Cell Transplantation

Cytomegalovirus-Seronegative Plus Leukoreduced Blood Products Are Still Superior to Only Leukoreduced Products in Preventing Transfusion-Transmitted Cytomegalovirus Infection

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only